Nephrogen

Nephrogen is a preclinical-stage biotechnology company developing curative genomic medicines for serious kidney and pancreatic diseases. The company utilizes its proprietary NeFIND™ platform, which combines artificial intelligence and high-throughput in vivo screening to engineer next-generation adeno-associated virus (AAV) delivery vehicles. These vectors are designed to be significantly more efficient and less immunogenic than existing technologies, specifically targeting the kidney and pancreas. Nephrogen's lead program focuses on Autosomal Dominant Polycystic Kidney Disease (ADPKD), aiming to provide a one-time curative treatment. Founded by a team of experts from Stanford and Harvard, the company is positioned at the intersection of computational biology and advanced gene editing.